The 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting just wrapped up in Philadelphia, Pennsylvania. From February 27 through March 2, the 2026 AAAAI Annual Meeting was four days packed with insightful conversations and research presentations on everything related to allergy and immunology.
Today, we are taking a look at some of the abstracts presented at the 2026 AAAAI Annual Meeting that focus on asthma and asthma-related topics. These abstracts, along with all the other abstracts presented at the annual meeting, were published in the Journal of Clinical Allergy and Immunology’s February 2026 issue. Some descriptions and conclusions were edited for brevity and clarity. For a complete look at all the abstracts presented, view the complete February 2026 issue of The Journal of Allergy and Clinical Immunology.
- Description: Recent studies suggest a potential association between glucagon-like peptide-1 receptor agonists (GLP-1) and reduced asthma exacerbations, though findings remain preliminary and largely limited to populations with diabetes.
- Conclusion: In the largest real world retrospective cohort comparison study to date, GLP-1 treatment was significantly associated with reduced exacerbation risk in asthmatics without diabetes across all excess weight groups.
Cat vs. Dog: Global Analysis of Pet Sensitization Impacts on Asthma Exacerbations
- Description: [The researchers] previously reported that in moderate-severe urban asthmatic cohorts, exacerbation severity markers (eosinophils, IgE, PFTs) did not differ between cat or dog mono- or dual-sensitized groups (AJRCCM, vol. 211, A1364, 2025). However, it remains unclear whether asthma exacerbations differ among these sensitized groups.
- Conclusion: Utilizing the TriNetX global health database, [the researchers] found asthmatics mono-sensitized to cats exhibited higher frequencies of asthma exacerbations and hospitalizations compared to dog mono-, dual-, and non-sensitized groups. Surprisingly, those mono-sensitized to dogs showed no significant differences in exacerbations compared to dual- and non-sensitized patients. [The research team’s] data suggest all respiratory clinicians should prioritize detecting cat sensitization and need for mitigation measures.
- Description: Exposure to mold in housing is associated with adverse asthma outcomes, but correlations between quantitative fungal measurement techniques and asthma remain low. These measurements focus on the presence of species, but shifting our focus to measuring indicators of fungal growth could and has led to stronger associations with asthma. The goal of this study is to develop an improved method for quantitative identification of harmful fungal growth in indoor spaces.
- Conclusion: [The research team’s] novel method allowed [them] to obtain high-quality fungal RNA from homes of children with asthma in NYC. The identified growth-associated genes in these samples may prove to be a better indicator of harmful mold growth in these homes compared to species-based mold measurement methods.
- Description: Asthma is a prevalent chronic respiratory disease that significantly impacts the quality of life for patients, particularly among children. The objective of this study was to evaluate the efficacy of a cloud-integrated smart management system for pediatric asthma, in comparison to traditional management approaches.
- Conclusion: The cloud-integrated pediatric asthma smart management system significantly improves asthma control, reduces acute exacerbations and associated healthcare costs, and enhances both patient and caregiver quality of life.
- Description: Children with moderate-to-severe asthma often experience exacerbations requiring systemic corticosteroid treatment even with regular use of inhaled corticosteroids. [The researchers] examined characteristics and systemic corticosteroid use patterns for children (6–11 years) with uncontrolled moderate-to-severe asthma despite adherence to inhaled corticosteroids (proportion of days covered ≥80%).
- Conclusion: Despite inhaled corticosteroids treatment, children with uncontrolled, moderate-to-severe asthma had considerable systemic corticosteroid use, with 1 in 5 receiving ≥5 systemic corticosteroid prescriptions in a year, suggesting they could benefit from additional treatment to control their disease.
Outcomes and Challenges with Biologic Treatments for Severe Asthma in a Safety Net Healthcare System
- Description: Severe asthma accounts for increasing healthcare resource utilization due to exacerbations and prescription costs which disproportionally affect lower socioeconomic status populations. This study aimed to determine the response to biologic therapy and barriers to treatment in a safety-net system.
- Conclusion: Biologic therapy for severe asthma was associated with decreased reported exacerbations in our cohort, but barriers affecting initiation and continuation were common.
Biologic Adherence and Exacerbation Risk Among Patients With Severe Asthma in the CHRONICLE Study
- Description: The relationship between biologic adherence and reduction in the annualized asthma exacerbation rate (52 weeks pre- to 52 weeks post-biologic initiation) was analyzed (in biologics combined and individually) for patients who experienced ≥2 exacerbations in the prior year using a locally estimated scatterplot smoothing model. Asthma exacerbations were defined as worsening symptoms requiring treatment with systemic corticosteroids and/or hospitalization.
- Conclusion: Among US adults with uncontrolled severe asthma, lower biologic adherence was associated with reduced real-world treatment effectiveness in terms of reducing exacerbations.
Sign up for alerts and stay informed on the latest published guidelines and articles.
Copyright © 2026 Guideline Central, all rights reserved.